Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;15(2):250-252.
doi: 10.21037/jtd-22-1699. Epub 2023 Feb 6.

Is a single port enough for the learned thoracic surgeons?

Yojiro Yutaka  1 , Hiroshi Date  1
Affiliations
Editorial

Is a single port enough for the learned thoracic surgeons?

Yojiro Yutaka et al. J Thorac Dis. .
No abstract available

Keywords: Uniportal segmentectomy; localization; margin; nonpalpable tumor; radiofrequency identification marking.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1699/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Wang G, Yu Z, Li J, et al. Anatomical segmentectomy under uniportal video-assisted thoracoscopic surgery for early staged non-small cell lung cancer: a case report. J Thorac Dis 2022;14:3613-23. 10.21037/jtd-21-1624 - DOI - PMC - PubMed
    1. Baue AE. Landmark perspective: Evarts A. Graham and the first pneumonectomy. JAMA 1984;251:260-4. 10.1001/jama.251.2.260 - DOI - PubMed
    1. CAHAN WG . Radical lobectomy. J Thorac Cardiovasc Surg 1960;39:555-72. - PubMed
    1. Lewis RJ, Sisler GE, Caccavale RJ. Imaged thoracic lobectomy: should it be done? Ann Thorac Surg 1992;54:80-3. 10.1016/0003-4975(92)91144-x - DOI - PubMed
    1. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022;399:1607-17. 10.1016/S0140-6736(21)02333-3 - DOI - PubMed